Lara Jr., P.N., Chansky, K., Davies, A.M., Franklin, W.A., Gumerlock, P.H., Guaglianone, P.P., Atkins, J.N., Farneth, N., Mack, P.C., Crowley, J.J. and Gandara, D.R. (2006) Bortezomib [PS-341] in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial [S0327]. Journal of Thoracic Oncology, 1, 996-1001. http://dx.doi.org/10.1097/01243894-200611000-00013

has been cited by the following article:

• TITLE: Missing the Target?—Targeted Therapy in Small Cell Lung Cancer

  AUTHORS: Karin R. Purshouse

  KEYWORDS: Oncology, Small Cell Lung Cancer, Targeted Therapy, Drug Development

  JOURNAL NAME: Advances in Lung Cancer, Vol.3 No.3, August 22, 2014

  ABSTRACT: Small cell lung cancer [SCLC] is a devastating form of cancer, with most patients harbouring extensive disease at diagnosis and survival of less than 5% at five years. Progress in novel therapies has been limited. This specialist review explores current targeted therapy options and potential areas of development.